Banner Life Sciences mourns the loss of its president, Michael Lytton...

EVER GROWING

From the leader in gelatin to a leading innovator in specialty pharmaceuticals

 
 
 
  • 1994
  • 1999
  • 2012
  • Today
 

Getting Started 1994 – 1998  

  • Sobel NV, a leading gelatin raw-materials provider, forms Banner Pharmacaps Inc. to extend capabilities into finished softgel products

  • High Point, North Carolina manufacturing facility opens

  • Banner becomes a leading contract-manufacturing organization initially focusing on nutritional softgel formulations

Building Technological Expertise and Capabilities 1999 – 2011  

  • Establishes R&D and regulatory capabilities

  • Develops several proprietary softgel-formulation technologies that offer clinical and commercial advantages over traditional softgels

  • Completes regulatory filings for multiple NDAs and ANDAs

  • Establishes and expands partnerships for commercializing Banner products

Expanding Commercial Presence 2012 – 2014  

  • Patheon Inc., a global leader in contract manufacturing, acquires Banner Pharmacaps Inc. to add both softgel-manufacturing capabilities and a proprietary products and technology business

  • Banner establishes direct-to-market capabilities for commercializing prescription ANDA products under the Banner label

  • Banner creates and expands a network of manufacturing and packaging partners

  • Patheon merges with DSM Pharmaceutical Products to form DPx Holdings B.V., which becomes the parent company of Patheon, DPx Fine Chemicals, and Banner Life Sciences™

Today

Today, Banner Life Sciences operates as an independent company, separate from Patheon, further supporting the transformation of Banner Life Sciences into a specialty pharmaceutical company. Banner Life Sciences and Patheon remain strategic business partners, with Patheon serving as the principal manufacturing organization for Banner Life Sciences.

Banner Life Sciences’ future is rooted in technology innovation and R&D that has evolved well beyond softgel products. By leveraging our formulation and pharmaceutical-development knowledge, we are able to offer a variety of dosage forms that help solve a wide range of unmet clinical needs.